Clinical trial · Interventional
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
A Phase I Study to Determine the Safety and Tolerability of BI 3820768 in Patients With Advanced Relapsed or Refractory Germ Cell Tumours, Endometrial Cancer, or Ovarian Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is open to adults with advanced germ cell tumours, endometrial cancer, or ovarian cancer whose previous treatments were not successful. People can join the study if they have no remaining treatment options or if standard therapy is not suitable. The purpose of this study is to test increasing doses of BI 3820768 to find a dose that people with these types of cancer can tolerate and that may make tumours shrink. BI 3820768 is a type of treatment that may help the immune system fight cancer. This is the first time BI 3820768 is being tested in humans. The study has 2 parts based on the way BI 3820768 is given. Depending on when participants join the study, they will receive BI 3820768 through one of two ways to inject the study medicine. All participants receive the study medicine. The medicine is given as an injection once a week for 2 cycles of 3 weeks each, followed by doses every 3 weeks. Participants are in the study for up to 3 years if they are benefiting from the treatment. During this time, they visit the study site regularly, and some visits will require overnight stays. Doctors will regularly check the size of the tumour and whether it has spread. Researchers want to find the highest dose of BI 3820768 that participants can tolerate by looking at the number of participants with certain severe health problems. The doctors also regularly check participants' health, take blood samples, and note any unwanted effects.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Relapsed or Refractory Endometrial Cancer | — | UNRESOLVED | — |
| Advanced Relapsed or Refractory Germ Cell Tumours | — | UNRESOLVED | — |
| Advanced Relapsed or Refractory Ovarian Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| BI 3820768 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Part 1: BI 3820768
- interventionNames
- Drug: BI 3820768
- type
- EXPERIMENTAL
- label
- Part 2: BI 3820768
- interventionNames
- Drug: BI 3820768
Primary outcomes (2)
- measure
- Occurrence of treatment-emergent AEs
- timeFrame
- up to 3 years.
- description
- AEs=Adverse Events
- measure
- Occurrence of DLT(s)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria : 1. Patient must be ≥18 years of age and at least at the legal age of consent in countries where it is older than 18 years at the time of signature on the informed consent forms (ICFs). 2. For patients with endometrial cancer (EC) and ovarian cancer (OVC), signed and dated written ICF1 for target testing. 3. Signed and dated ICF2 for all patients describing the study in accordance with International Council on Harmonisation Good Clinical Practice (ICH-GCP) and local legislation prior to any trial-specific procedures, sampling, or analyses. 4. Prior to Screening Visit 02, confirmed target-positivity for EC and OVC based on central laboratory testing of tumour tissue sample. 5. Patients with a histologically or cytologically confirmed diagnosis of germ cell tumour (GCT), EC, or OVC. 6. Patients with advanced, relapsed/refractory (r/r) GCT, EC, or OVC. 7. Patients with disease progression despite conventional treatment, intolerant to or not a candidate for conventional treatment, who have exhausted all established treatment options. 8. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Further inclusion criteria apply. Exclusion criteria: 1. Patient with a history of a major surgery within 28 days prior to the first dose of BI 3820768 (major according to the Investigator's and/or Sponsor's assessment). 2. Previous or concomitant malignancies other than the one treated in this trial within the past 3 years except: 1. Effectively treated non-melanoma skin cancers 2. Effectively treated carcinoma in situ of the cervix 3. Effectively treated ductal carcinoma in situ 4. Other effectively treated malignancy that is considered cured by local treatment 3. Patient with known leptomeningeal disease or spinal cord compression due to disease. 4. Presence of any infection requiring systemic antimicrobial treatment within 7 days prior to the first dose of trial medication. Patients who have any clinical signs of infection (e.g. fever or leukocytosis) within 48 h prior to the first dose of trial medication are not eligible. 5. Patients with Hepatitis-C-Virus (HCV) infection, defined as: 1. Currently receiving curative antiviral treatment for HCV infection, and/or 2. HCV viral load is above the limit of quantification (HCV RNA positive). 6. Patients with active hepatitis B virus (HBV) infection (chronic or acute); defined as having a positive hepatitis B surface antigen (HBsAg), and HBsAg test at screening. 7. Patient with past HBV infection or resolved HBV infection (defined as the presence of hepatitis B core antibody (HBcAb) and absence of HbsAg) are eligible. HBV DNA must be obtained in these patients prior study start. Further exclusion criteria apply.
References
Publications (0)
Data not yet available